IAP6 Rec'd PCT/PTO 01 SEP 2006
ATTORNEY'S DOCKET NUMBER

TRANSMITTAL LETTER TO THE UNITED STATES **DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A SUBMISSION UNDER 35 U.S.C. 371**

65084.000023

U.S. APPLICATION NO. (if known, see 37 CFR 1.5)

INTERNATIONAL	APPLICATION	NO.

INTERNATIONAL FILING DATE

	P	C1/EP2005/002450 March 4, 2005 March 5, 2004				
		WITH REDUCED ACTIVITY OF A STARCH PHOSPHORYLATING ENZYME				
APPLICANT(S) FOR DO/EO/US						
		OHBERG Oliver KOETTING Gerhard RITTE Martin STEUP				
Appli	cant h	erewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:				
1.	\boxtimes	This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.				
2.		This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.				
3.	\boxtimes	This express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.				
Ä .	\boxtimes	The US has been elected (Article 31).				
5.	\boxtimes	A copy of the International Application as filed (35 U.S.C. 371(c)(2))				
	a.	is attached hereto (required only if not communicated by the International Bureau).				
	b.	has been communicated by the International Bureau.				
	c.	is not required, as the application was filed in the United States Receiving Office (RO/US).				
6.		An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).				
	a.	is attached hereto.				
	b.	has been previously submitted under 35 U.S.C. 154(d)(4).				
7.	⊠ a.	Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) are attached hereto (required only if not communicated by the International Bureau).				
	b.	have been communicated by the International Bureau.				
	c.	have not been made; however, the time limit for making such amendments has NOT expired.				
	d.	★ have not been made and will not be made.				
8.		An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).				
9.	\boxtimes	A copy of the oath or declaration of the inventor(s) as filed in the PCT Request (35 U.S.C. 371(c)(4)).				
10.		An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).				
Item	s 11 to	20 below concern document(s) or information included:				
11.	\boxtimes	An Information Disclosure Statement under 37 CFR 1.97 and 1.98.				
12.	\boxtimes	An Assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.				
13.	\boxtimes	A Preliminary Amendment.				
14.	\boxtimes	An Application Data Sheet under 37 CFR 1.76.				
15.		A substitute specification.				
16.	\boxtimes	A power of attorney and/or change of address letter.				
17.	\boxtimes	A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821-1.825.				
18.		A second copy of the published International Application under 35 U.S.C. 154(d)(4).				
19.		A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).				
20.		Other items or information:				
	¥					

dPCT/PTO 01 SEP 2006 U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR 1.7) 0/591540 PCT/EP2005/002450 65084.000023 **PTO USE** CALCULATIONS The following fees have been submitted: Basic National Fee (37 CFR 1.492(a)) 300.00 \$ 300.00 21. Examination Fee (37 CFR 1.492(c)) 22. If the written opinion prepared by ISA/US or the International Preliminary Examination Report prepared 200.00 0.00by IPEA/US indicates all claims satisfy provisions of PCT Article 33(1)-(4) \$ 200.00 All other situations \boxtimes Search Fee (37 CFR 1.492(b)) 23. If the written opinion of the ISA/US or the International Preliminary Examination Report prepared by IPEA/US indicates all claims satisfy provisions of PCT Article 33(1)-(4) 0.00Search Fee (37 CFR 1.445(a)(2)) has been paid on the international application to the USPTO as an 400.00 \$ 100.00 International Searching Authority International Search Report prepared by an ISA other than the US and provided to the Office or \$ 400.00 previously communicated to the US by the IB \$ 500.00 All other situations \$ 900.00 **TOTAL OF ABOVE CALCULATIONS =** \$ M Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing in compliance with 37 CFR 1.821(c) or (e) or computer program listing filed in an electronic medium) (37 CFR 1.492(i)). The fee is \$250.00 for each additional 50 sheets of paper or fraction Number of each additional 50 or fraction thereof Total Sheets Extra Sheets **RATE** (round up to a whole number) **120** - 100 20 /50 x \$250.00 250.00 Surcharge of \$130.00 for furnishing any of the search fee, examination fee, or the oath or declaration after \$ the date of commencement of the national stage (37 CFR 1.492(h)) NUMBER FILED NUMBER EXTRA **CLAIMS RATE** \$ 8 28 - 20 =X \$ 50.00 \$ 400.00 Total claims 2 - 3 =\$200.00 \$ x Independent claims \$360.00 \$ MULTIPLE DEPENDENT CLAIM(S) (if applicable) TOTAL OF ABOVE CALCULATIONS = \$ 1,550.00 \$ Applicant claims small entity status. See 37 CFR 1.27. The fees above are reduced by 1/2. \$ 1,550.00 SUBTOTAL = Processing fee of \$130.00 for furnishing the English translation later than 30 months from the earliest \$ claimed priority date (37 CFR 1.492(f)). \$ TOTAL NATIONAL FEE = 1,550.00 Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an \$ 40.00 appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property \$ 1,590.00 TOTAL FEES ENCLOSED = Amount to \$ be refunded: Amount to \$ be charged:

IAP9 REC'O PCT/PTO 01 SEP 2008				
U.S. APPLICATION NO. (IF KNOWN SEE 37.CFR 1.7) 10/591540	INTERNATIONAL APPLICATION NO. PCT/EP2005/002454	65084.000020		
a. A check in the amount of \$1,590.00	to cover the above fees is enclosed.			
b. Please charge Deposit Account No.	<u>50-0206</u> in the amount of \$	to cover the above fees.		
A duplicate copy of this sheet is enclosed.				
	The Commissioner is hereby authorized to charge any additional fees which may be required, or credit to Deposit Account No. 50-0206 A duplicate copy of this sheet is enclosed.			
d. Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.				
NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.				
SEND ALL CORRESPONDENCE TO:				
CUSTOMER NO. 21967 Intellectual Property Department	SIGNATURE Dans Blechmann			
Hunton & Williams LLP 1900 K Street, N.W.; Suite 1200	Dana Z. Buschmann			
Washington, DC 20006-1109 (202) 955-1500 (telephone)	NAME 54,567			
(202) 778-2201 (facsimile)	REGISTRATION NUMBER D	ATE 9/1/06		



HUNTON& WILLIAMS

1900 K STREET, N.W. WASHINGTON, D.C. 20006-1109

TEL 202 • 955 • 1500 FAX 202 • 778 • 2201

ROBERT M. SCHULMAN DIRECT DIAL: 202-955-1928 EMAIL: rschulman@hunton.com

DANA Z. BUSCHMANN
DIRECT DIAL: 202-955-1939
EMAIL: dbuschmann@hunton.com

FILE NO: 65084.000023

August 23, 2006

Via E-Mail

Dr. Martin Quanz Bayer BioScience GmbH Hermannswerder 20a D-14473 Potsdam Germany

Re:

U.S. National Stage Application of PCT/EP2005/002450

PLANTS WITH REDUCED ACTIVITY OF A STARCH

PHOSPHORYLATING ENZYME Your Ref.: BCS 04-5004 US Our Ref.: 65084.00023

Dear Dr. Quanz:

Thank you for your letter of August 15, 2006, enclosing the signed Assignment and Power of Attorney forms. Please note that the signed Declaration was not included. We have attached a Declaration for your convenience. Kindly have the inventors sign and date this Declaration and return it to us for filing with the application.

If we do not receive the signed Declaration by August 31, 2006, we will file the application with an unsigned Declaration.

Please also provide us with copies of XP002349835 (Alonso et al.); XP002349836 (Koetting et al.); and ACC. No.: SALK_110814 (alias N610814) listed on the literature chart enclosed with your letter. We will need to provide a copy of each of these publications with the Information Disclosure Statement.

Sincerely,

Dana Z. Buschmann DZB/tmf Enclosure